Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool

The main objective of this investigation was to develop an in vitro–in vivo correlation (IVIVC) for immediate release candesartan cilexetil formulations by designing an in vitro dissolution test to be used as development tool. The IVIVC could be used to reduce failures in future bioequivalence studies. Data from two bioequivalence studies were scaled and combined to obtain the dataset for the IVIVC. Two-step and one-step approaches were used to develop the IVIVC. Experimental solubility and permeability data confirmed candesartan cilexetil. Biopharmaceutic Classification System (BCS) class II candesartan average plasma profiles were deconvoluted by the Loo-Riegelman method to obtain the oral fractions absorbed. Fractions dissolved were obtained in several conditions in USP II and IV apparatus and the results were compared calculating the f2 similarity factor. Levy plot was constructed to estimate the time scaling factor and to make both processes, dissolution and absorption, superimposable. The in vitro dissolution experiment that reflected more accurately the in vivo behavior of the products of candesartan cilexetil employed the USP IV apparatus and a three-step pH buffer change, from 1.2 to 4.5 and 6.8, with 0.2% of Tween 20. This new model was able to predict the in vivo differences in dissolution and it could be used as a risk-analysis tool for formulation selection in future bioequivalence trials.

[1]  Christel A. S. Bergström,et al.  Selection of In Vivo Predictive Dissolution Media Using Drug Substance and Physiological Properties , 2020, The AAPS Journal.

[2]  Andrés Felipe Chamorro Rengifo,et al.  Understanding the interaction between Soluplus® and biorelevant media components. , 2019, Colloids and surfaces. B, Biointerfaces.

[3]  M. El-Badry,et al.  A self-nanoemulsifying drug delivery system for enhancing the oral bioavailability of candesartan cilexetil: Ex-vivo and in-vivo evaluation. , 2019, Journal of pharmaceutical sciences.

[4]  C. D. Kaur,et al.  Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug. , 2019, Recent patents on drug delivery & formulation.

[5]  Sarfaraz K. Niazi.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.

[6]  M. Bermejo,et al.  Determination of intestinal permeability using in situ perfusion model in rats: Challenges and advantages to BCS classification applied to digoxin , 2018, International journal of pharmaceutics.

[7]  S. Ibrić,et al.  Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro‐in silico approach , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  B Abrahamsson,et al.  Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development. , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  J. Cardot,et al.  Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach , 2018, The AAPS Journal.

[10]  A. Zaid,et al.  Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets , 2018, Clinical pharmacology in drug development.

[11]  M. Bermejo,et al.  In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. , 2018, Molecular pharmaceutics.

[12]  Beom-Jin Lee,et al.  In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism. , 2017, Current drug metabolism.

[13]  M. Bermejo,et al.  Comparison of segmental‐dependent permeability in human and in situ perfusion model in rat , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  O. Abdallah,et al.  Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies , 2017, AAPS PharmSciTech.

[15]  M. Bermejo,et al.  IVIVC approach based on carbamazepine bioequivalence studies combination. , 2017, Die Pharmazie.

[16]  S. Arora,et al.  Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability , 2016, Drug Delivery and Translational Research.

[17]  B. Nanjwade,et al.  Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation , 2014, Drug delivery.

[18]  N. Yuksel,et al.  In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations. , 2016, International journal of biological macromolecules.

[19]  Naveen Chella,et al.  Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[20]  Marival Bermejo,et al.  In vitro–in vivo correlations: general concepts, methodologies and regulatory applications , 2015, Drug development and industrial pharmacy.

[21]  B. Nanjwade,et al.  Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor , 2015, Drug development and industrial pharmacy.

[22]  Talia Flanagan,et al.  In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  M. Sznitowska,et al.  The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media , 2014, AAPS PharmSciTech.

[24]  J. Cardot,et al.  In vitro–In Vivo Correlations: Tricks and Traps , 2012, The AAPS Journal.

[25]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[26]  S. Klein,et al.  Can Biorelevant Media be Simplified by using SLS and Tween 80 to Replace Bile Compounds , 2010 .

[27]  J. Dressman,et al.  Gastric juice as a dissolution medium: Surface tension and pH , 1998, European Journal of Drug Metabolism and Pharmacokinetics.

[28]  Shamim A. Momin,et al.  Comparative Analysis of the Properties of Tween‐20, Tween‐60, Tween‐80, Arlacel‐60, and Arlacel‐80 , 2007 .

[29]  J. Simiand,et al.  Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Y. Yoshimura,et al.  Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. , 1996, Arzneimittel-Forschung.

[31]  H Humbert,et al.  In vitro-in vivo correlation of a modified-release oral form of ketotifen: in vitro dissolution rate specification. , 1994, Journal of pharmaceutical sciences.

[32]  L. Dittert,et al.  Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. , 1969, Journal of pharmaceutical sciences.